• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

OLANZAPINE Drug Record

  • Summary
  • Interactions
  • Claims
  • OLANZAPINE chembl:CHEMBL715 Approved

    Alternate Names:

    ZYPREXA
    OLANZAPINE
    LY170053
    LY-170053
    ARKOLAMYL
    ZYPREXA ZYDIS
    ZALASTA
    pubchem.compound:4585
    OLANZAPINUM
    OLANZAPINA
    2-METHYL-4-(4-METHYL-1-PIPERAZINYL)-10H-THIENO[2,3-B][1,5]BENZODIAZEPINE
    OLANZAPIN
    drugbank:00334
    chemidplus:132539-06-1
    chembl:CHEMBL715
    rxcui:61381

    Drug Info:

    Drug Indications antidepressant,for treatment of bipolar disorder
    FDA Approval approved
    Drug Class Small Molecule
    Drug Indications antipsychotic agent
    Year of Approval 1996
    Drug Class antipsychotic agents
    (3 More Sources)

    Publications:

    Arranz MJ et al., 1998, Lack of association between a polymorphism in the promoter region of the dopamine-2 receptor gene and clozapine response., Pharmacogenetics
    Eum S et al., 2017, Pharmacogenetic evaluation to assess breakthrough psychosis with aripiprazole long-acting injection: a case report., BMC Psychiatry
    Sukasem C et al., 2016, Impact of Pharmacogenetic Markers of CYP2D6 and DRD2 on Prolactin Response in Risperidone-Treated Thai Children and Adolescents With Autism Spectrum Disorders., J Clin Psychopharmacol
    Blasi G et al., 2015, Variation in Dopamine D2 and Serotonin 5-HT2A Receptor Genes is Associated with Working Memory Processing and Response to Treatment with Antipsychotics., Neuropsychopharmacology
    López-Rodríguez R et al., 2013, Pharmacodynamic genetic variants related to antipsychotic adverse reactions in healthy volunteers., Pharmacogenomics
    Roke Y et al., 2013, The effect of the Taq1A variant in the dopamine D₂ receptor gene and common CYP2D6 alleles on prolactin levels in risperidone-treated boys., Pharmacogenet Genomics
    Houston JP et al., 2012, Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia., J Clin Psychiatry
    Houston J et al., 2011, Association of DRD2 and ANKK1 polymorphisms with prolactin increase in olanzapine-treated women., Psychiatry Res
    Müller DJ et al., 2012, Systematic analysis of dopamine receptor genes (DRD1-DRD5) in antipsychotic-induced weight gain., Pharmacogenomics J
    Hong CJ et al., 2010, Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment., Pharmacogenet Genomics
    Zhang JP et al., 2010, D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis., Am J Psychiatry
    Yasui-Furukori N et al., 2008, Association between dopamine-related polymorphisms and plasma concentrations of prolactin during risperidone treatment in schizophrenic patients., Prog Neuropsychopharmacol Biol Psychiatry
    Bakker PR et al., 2008, Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions., Mol Psychiatry
    Alenius M et al., 2008, Gene polymorphism influencing treatment response in psychotic patients in a naturalistic setting., J Psychiatr Res
    Zai CC et al., 2007, Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients., Mol Psychiatry
    Suzuki A et al., 2001, The -141C Ins/Del polymorphism in the dopamine D2 receptor gene promoter region is associated with anxiolytic and antidepressive effects during treatment with dopamine antagonists in schizophrenic patients., Pharmacogenetics
    Batra S, 1976, Unconjugated estradiol in the myometrium of pregnancy., Endocrinology
    Ohara K et al., 1998, Functional polymorphism of -141C Ins/Del in the dopamine D2 receptor gene promoter and schizophrenia., Psychiatry Res
    Li T et al., 1998, Case-control, haplotype relative risk and transmission disequilibrium analysis of a dopamine D2 receptor functional promoter polymorphism in schizophrenia., Schizophr Res
    Shen YC et al., 2009, Effects of DRD2/ANKK1 gene variations and clinical factors on aripiprazole efficacy in schizophrenic patients., J Psychiatr Res
    Xing Q et al., 2007, The relationship between the therapeutic response to risperidone and the dopamine D2 receptor polymorphism in Chinese schizophrenia patients., Int J Neuropsychopharmacol
    Lencz et al., 2006, DRD2 promoter region variation as a predictor of sustained response to antipsychotic medication in first-episode schizophrenia patients., Am J Psychiatry
    Lerman C et al., 2006, Role of functional genetic variation in the dopamine D2 receptor (DRD2) in response to bupropion and nicotine replacement therapy for tobacco dependence: results of two randomized clinical trials., Neuropsychopharmacology
    Hwang R et al., 2005, Association study of 12 polymorphisms spanning the dopamine D(2) receptor gene and clozapine treatment response in two treatment refractory/intolerant populations., Psychopharmacology (Berl)
    Wu et al., 2005, Response to chlorpromazine treatment may be associated with polymorphisms of the DRD2 gene in Chinese schizophrenic patients., Neurosci. Lett.
    Yamanouchi Y et al., 2003, Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone., Pharmacogenomics J
    Li T et al., 2002, Allelic association analysis of the dopamine D2, D3, 5-HT2A, and GABA(A)gamma2 receptors and serotonin transporter genes with heroin abuse in Chinese subjects., Am J Med Genet
    Thacker et al., 2006, The effects of adulthood olanzapine treatment on cognitive performance and neurotrophic factor content in male and female rats neonatally treated with quinpirole., Eur. J. Neurosci.
    Weizman et al., 2003, The antinociceptive effect of amisulpride in mice is mediated through opioid mechanisms., Eur. J. Pharmacol.
    Naiker et al., 2006, Dose determination of haloperidol, risperidone and olanzapine using an in vivo dopamine D2-receptor occupancy method in the rat., Eur. J. Pharmacol.
    Uchida et al., 2007, Brain neurotransmitter receptor-binding characteristics in rats after oral administration of haloperidol, risperidone and olanzapine., Life Sci.
    Jordan et al., 2007, In vitro functional characteristics of dopamine D2 receptor partial agonists in second and third messenger-based assays of cloned human dopamine D2Long receptor signalling., J. Psychopharmacol. (Oxford)
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Nasrallah, 2008, Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles., Mol. Psychiatry
    Brafford MV et al., 2014, Olanzapine: an antiemetic option for chemotherapy-induced nausea and vomiting., J Adv Pract Oncol
    Tiwari AK et al., 2010, Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients., Prog Neuropsychopharmacol Biol Psychiatry
    Bymaster et al., 1999, Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro., Schizophr. Res.
    Ono S et al., 2015, GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine., J Neuropsychiatry Clin Neurosci
    Ono S et al., 2012, Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine., Pharmacogenomics J
    Kao AC et al., 2014, Methylenetetrahydrofolate reductase gene variants and antipsychotic-induced weight gain and metabolic disturbances., J Psychiatr Res
    Söderberg MM et al., 2013, Influence of CYP1A1/CYP1A2 and AHR polymorphisms on systemic olanzapine exposure., Pharmacogenet Genomics
    Shahid et al., 2009, Asenapine: a novel psychopharmacologic agent with a unique human receptor signature., J. Psychopharmacol. (Oxford)
    Fernández et al., 2005, Discovery of new tetracyclic tetrahydrofuran derivatives as potential broad-spectrum psychotropic agents., J. Med. Chem.
    Crisafulli C et al., 2012, Case-control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics., Eur Arch Psychiatry Clin Neurosci
    Hutchison et al., 2006, The effect of olanzapine on craving and alcohol consumption., Neuropsychopharmacology
    Adams DH et al., 2008, Dopamine receptor D3 genotype association with greater acute positive symptom remission with olanzapine therapy in predominately caucasian patients with chronic schizophrenia or schizoaffective disorder., Hum Psychopharmacol
    Porcelli S et al., 2016, PDE7B, NMBR and EPM2A Variants and Schizophrenia: A Case-Control and Pharmacogenetics Study., Neuropsychobiology
    Chagnon YC et al., 2007, Possible association of the pro-melanin-concentrating hormone gene with a greater body mass index as a side effect of the antipsychotic olanzapine., Am J Med Genet B Neuropsychiatr Genet
    Delacrétaz A et al., 2017, Association of variants in SH2B1 and RABEP1 with worsening of low-density lipoprotein and glucose parameters in patients treated with psychotropic drugs., Gene
    Altschuler et al., 2005, Using histamine (H1) antagonists, in particular atypical antipsychotics, to treat anemia of chronic disease via interleukin-6 suppression., Med. Hypotheses
    Poyurovsky et al., 2005, The effect of betahistine, a histamine H1 receptor agonist/H3 antagonist, on olanzapine-induced weight gain in first-episode schizophrenia patients., Int Clin Psychopharmacol
    Rasmussen et al., 2005, Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine., J. Pharmacol. Exp. Ther.
    Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol
    Nikolac Perkovic M et al., 2014, Association between the brain-derived neurotrophic factor Val66Met polymorphism and therapeutic response to olanzapine in schizophrenia patients., Psychopharmacology (Berl)
    Zhang JP et al., 2016, Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis., Schizophr Bull
    Czerwensky F et al., 2013, MC4R rs489693: a clinical risk factor for second generation antipsychotic-related weight gain?, Int J Neuropsychopharmacol
    Nurmi EL et al., 2013, Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies., Transl Psychiatry
    Malhotra AK et al., 2012, Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain., Arch Gen Psychiatry
    Chowdhury NI et al., 2013, Genetic association study between antipsychotic-induced weight gain and the melanocortin-4 receptor gene., Pharmacogenomics J
    Maffioletti E et al., 2020, Association study between HTR2A rs6313 polymorphism and early response to risperidone and olanzapine in schizophrenia patients., Drug Dev Res
    Salloum NC et al., 2014, Towards the clinical implementation of pharmacogenetics in bipolar disorder., BMC Med
    Laika B et al., 2010, Pharmacogenetics and olanzapine treatment: CYP1A2*1F and serotonergic polymorphisms influence therapeutic outcome., Pharmacogenomics J
    Angelucci F et al., 2009, Delusion symptoms and response to antipsychotic treatment are associated with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's disease: a 3-year follow-up longitudinal study., J Alzheimers Dis
    Ujike H et al., 2008, Multiple genetic factors in olanzapine-induced weight gain in schizophrenia patients: a cohort study., J Clin Psychiatry
    Thomas P et al., 2008, Correlates of response to Olanzapine in a North Indian Schizophrenia sample., Psychiatry Res
    Moresco et al., 2004, Cerebral D2 and 5-HT2 receptor occupancy in Schizophrenic patients treated with olanzapine or clozapine., J. Psychopharmacol. (Oxford)
    Yatham et al., 2005, Atypical antipsychotics in bipolar depression: potential mechanisms of action., J Clin Psychiatry
    McDonald et al., 2003, Enhancement of latent inhibition by two 5-HT2A receptor antagonists only when given at both pre-exposure and conditioning., Psychopharmacology (Berl.)
    Padín et al., 2006, Parallel regulation by olanzapine of the patterns of expression of 5-HT2A and D3 receptors in rat central nervous system and blood cells., Neuropharmacology
    Sharpley et al., 2005, Olanzapine increases slow wave sleep and sleep continuity in SSRI-resistant depressed patients., J Clin Psychiatry
    Söderberg MM et al., 2013, Influence of FMO1 and 3 polymorphisms on serum olanzapine and its N-oxide metabolite in psychiatric patients., Pharmacogenomics J
    Drago A et al., 2014, Genome-wide association study supports the role of the immunological system and of the neurodevelopmental processes in response to haloperidol treatment., Pharmacogenet Genomics
    Theisen et al., 2007, No evidence for binding of clozapine, olanzapine and/or haloperidol to selected receptors involved in body weight regulation., Pharmacogenomics J.
    Wood et al., 2006, Pharmacological profile of antipsychotics at monoamine receptors: atypicality beyond 5-HT2A receptor blockade., CNS Neurol Disord Drug Targets
    Overstreet et al., 2007, Drug challenges reveal differences in mediation of stress facilitation of voluntary alcohol drinking and withdrawal-induced anxiety in alcohol-preferring P rats., Alcohol. Clin. Exp. Res.
    Zhang et al., 2006, Distinct functional profiles of aripiprazole and olanzapine at RNA edited human 5-HT2C receptor isoforms., Biochem. Pharmacol.
    Hertel, 2006, Comparing sertindole to other new generation antipsychotics on preferential dopamine output in limbic versus striatal projection regions: mechanism of action., Synapse
    Ma X et al., 2014, HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis., Int J Psychiatry Clin Pract
    Mulder H et al., 2009, HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia: a replication study., J Clin Psychopharmacol
    De Luca V et al., 2007, HTR2C haplotypes and antipsychotics-induced weight gain: X-linked multimarker analysis., Hum Psychopharmacol
    Sicard MN et al., 2010, Polymorphisms of the HTR2C gene and antipsychotic-induced weight gain: an update and meta-analysis., Pharmacogenomics
    Mulder H et al., 2007, The association between HTR2C gene polymorphisms and the metabolic syndrome in patients with schizophrenia., J Clin Psychopharmacol
    Correia CT et al., 2010, Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions., Pharmacogenomics J
    Risselada AJ et al., 2012, Association between HTR2C gene polymorphisms and the metabolic syndrome in patients using antipsychotics: a replication study., Pharmacogenomics J
    Opgen-Rhein C et al., 2010, Association of HTR2C, but not LEP or INSIG2, genes with antipsychotic-induced weight gain in a German sample., Pharmacogenomics
    Dos Santos-Júnior A et al., 2016, Pharmacogenetics of Risperidone and Cardiovascular Risk in Children and Adolescents., Int J Endocrinol
    Godlewska BR et al., 2009, Olanzapine-induced weight gain is associated with the -759C/T and -697G/C polymorphisms of the HTR2C gene., Pharmacogenomics J
    Mulder H et al., 2007, The association between HTR2C polymorphisms and obesity in psychiatric patients using antipsychotics: a cross-sectional study., Pharmacogenomics J
    McClay JL et al., 2011, Genome-wide pharmacogenomic study of neurocognition as an indicator of antipsychotic treatment response in schizophrenia., Neuropsychopharmacology
    Mancama D et al., 2007, Choline acetyltransferase variants and their influence in schizophrenia and olanzapine response., Am J Med Genet B Neuropsychiatr Genet
    Söderberg MM et al., 2014, No influence of CYP3A43 rs472660G> A on steady-state serum olanzapine concentrations in white psychiatric patients., Pharmacogenet Genomics
    Bigos KL et al., 2011, Genetic variation in CYP3A43 explains racial difference in olanzapine clearance., Mol Psychiatry
    Brandl EJ et al., 2014, Genetic variation in the GCG and in the GLP1R genes and antipsychotic-induced weight gain., Pharmacogenomics
    Herken H et al., 2009, The association of olanzapine-induced weight gain with peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism in patients with schizophrenia., DNA Cell Biol
    Vázquez-Bourgon J et al., 2010, Serotonin transporter polymorphisms and early response to antipsychotic treatment in first episode of psychosis., Psychiatry Res
    Monteleone P et al., 2010, Endocannabinoid Pro129Thr FAAH functional polymorphism but not 1359G/A CNR1 polymorphism is associated with antipsychotic-induced weight gain., J Clin Psychopharmacol
    Tiwari AK et al., 2010, A common polymorphism in the cannabinoid receptor 1 (CNR1) gene is associated with antipsychotic-induced weight gain in Schizophrenia., Neuropsychopharmacology
    Brandl EJ et al., 2013, Exploratory study on association of genetic variation in TBC1D1 with antipsychotic-induced weight gain., Hum Psychopharmacol
    Wang R et al., 2018, ABCB1 1199G > A Polymorphism Impacts Transport Ability of P-gp-Mediated Antipsychotics., DNA Cell Biol
    Lin YC et al., 2006, The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia., Ther Drug Monit
    Srivastava V et al., 2008, Genetic correlates of olanzapine-induced weight gain in schizophrenia subjects from north India: role of metabolic pathway genes., Pharmacogenomics
  • OLANZAPINE   GIPR

    Interaction Score: 2.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25321336 21747410


    Sources:
    PharmGKB

  • OLANZAPINE   GSTM3

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23559402


    Sources:
    PharmGKB

  • OLANZAPINE   PMCH

    Interaction Score: 1.85

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17541984


    Sources:
    PharmGKB

  • OLANZAPINE   TBC1D1

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23364847


    Sources:
    PharmGKB

  • OLANZAPINE   SV2C

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OLANZAPINE   SPOPL

    Interaction Score: 0.92

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OLANZAPINE   HTR1E

    Interaction Score: 0.92

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   ANKK1

    Interaction Score: 0.77

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26872113 23859574 23851570 23559402 20714340 18579277 18180754 18086475 17767146


    Sources:
    PharmGKB

  • OLANZAPINE   FMO1

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23147717


    Sources:
    PharmGKB

  • OLANZAPINE   HTR2C

    Interaction Score: 0.48

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction Serotonin 2c (5-HT2c) receptor antagonist
    Direct Interaction yes
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

    PMIDs:
    16983399 16918396 17624999 10227113 11752352 16336943 16952163 22967772 25152019 19142101 17702092 21121776 19193342 17632216 19997080 20680028 20504252 26880915 27217270 19434072 17016522 25032030


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • OLANZAPINE   CYP3A43

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24595013 21519338


    Sources:
    PharmGKB

  • OLANZAPINE   MC4R

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27217270 23920449 23799528 22566560 22310352


    Sources:
    PharmGKB

  • OLANZAPINE   IL1A

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21107309


    Sources:
    PharmGKB

  • OLANZAPINE   EIF2AK4

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24751813


    Sources:
    PharmGKB

  • OLANZAPINE   DRD5

    Interaction Score: 0.28

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 10227113 25032030


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   EPM2A

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27092952


    Sources:
    PharmGKB

  • OLANZAPINE   HTR6

    Interaction Score: 0.25

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 25032030


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   FMO3

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23147717


    Sources:
    PharmGKB

  • OLANZAPINE   DRD2

    Interaction Score: 0.22

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

    PMIDs:
    9918131 28673279 26872113 25563748 23859574 23851570 22967772 21095016 20714340 20375926 20194480 18579277 18180754 18086475 17767146 11505224 991813 9858029 9713903 18926547 17105675 16513877 16123753 15830237 15694263 14610521 11920858 17067304 14575800 16730699 17316700 17092971 11752352 17848919 25032030


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • OLANZAPINE   CHRM4

    Interaction Score: 0.21

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 10227113 25032030


    Sources:
    TdgClinicalTrial TEND

  • OLANZAPINE   RABEP1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28694205


    Sources:
    PharmGKB

  • OLANZAPINE   TPMT

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23559402


    Sources:
    PharmGKB

  • OLANZAPINE   SH2B1

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28694205


    Sources:
    PharmGKB

  • OLANZAPINE   CHAT

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17503482


    Sources:
    PharmGKB

  • OLANZAPINE   ATP1A2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OLANZAPINE   HTR2A

    Interaction Score: 0.18

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    32462699 24885933 19636338 19494443 19193342 19000940 15358979 16038601 17316700 10227113 14530903 16905159 15816787 11752352 17848919 25032030


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • OLANZAPINE   GNB3

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19193342


    Sources:
    PharmGKB

  • OLANZAPINE   DRD4

    Interaction Score: 0.13

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

    PMIDs:
    16237394 11752352 25032030


    Sources:
    TdgClinicalTrial ChemblInteractions TEND

  • OLANZAPINE   LEP

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18681781


    Sources:
    PharmGKB

  • OLANZAPINE   CCKBR

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20732371


    Sources:
    PharmGKB

  • OLANZAPINE   CNR1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23799528 20631561 20107430


    Sources:
    PharmGKB

  • OLANZAPINE   GCG

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24624910


    Sources:
    PharmGKB

  • OLANZAPINE   DRD3

    Interaction Score: 0.11

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Mechanism of Interaction D2-like dopamine receptor antagonist
    Direct Interaction yes
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

    PMIDs:
    17848919 11752352 18320559 25032030


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB

  • OLANZAPINE   ADRA1B

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    10227113 17848919 17316700 11752352


    Sources:
    TdgClinicalTrial TEND

  • OLANZAPINE   CHRM2

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 10227113 25032030


    Sources:
    TdgClinicalTrial TEND

  • OLANZAPINE   CHRM5

    Interaction Score: 0.09

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 10227113


    Sources:
    TdgClinicalTrial TEND

  • OLANZAPINE   FAAH

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20631561


    Sources:
    PharmGKB

  • OLANZAPINE   CYP1A1

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23492908


    Sources:
    PharmGKB

  • OLANZAPINE   HTR1A

    Interaction Score: 0.08

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    22120873 17848919 25032030


    Sources:
    TdgClinicalTrial PharmGKB

  • OLANZAPINE   HTR1D

    Interaction Score: 0.08

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Novel drug target Established target
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv

    PMIDs:
    17848919


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   HTR7

    Interaction Score: 0.08

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   MTHFR

    Interaction Score: 0.07

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24725652


    Sources:
    PharmGKB

  • OLANZAPINE   HRH1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    15893120 15729086 17316700 10227113 11752352 16141369 25032030


    Sources:
    TdgClinicalTrial TEND

  • OLANZAPINE   CHRM1

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 17316700 10227113 25032030


    Sources:
    TdgClinicalTrial TEND

  • OLANZAPINE   CHRM3

    Interaction Score: 0.07

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 10227113 25032030


    Sources:
    TdgClinicalTrial TEND

  • OLANZAPINE   ADRB3

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19193342


    Sources:
    PharmGKB

  • OLANZAPINE   HTR3A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 25032030


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   HTR1B

    Interaction Score: 0.06

    Interaction Types & Directionality:
    agonist (activating)
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   SLC6A4

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23859574 20031235


    Sources:
    PharmGKB

  • OLANZAPINE   UGT1A1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23559402


    Sources:
    PharmGKB

  • OLANZAPINE   DRD1

    Interaction Score: 0.05

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    18308814 15771415 10227113 17848919 11752352 25032030


    Sources:
    TdgClinicalTrial TEND

  • OLANZAPINE   ADRA1A

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919 10227113 25032030


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   ADRA2B

    Interaction Score: 0.04

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name ALKS 3831
    Trial Name OREX-003, olanzapine plus zonisamide SR
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   AHR

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23492908


    Sources:
    PharmGKB

  • OLANZAPINE   ADRA2C

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   COMT

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OLANZAPINE   BDNF

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24595507


    Sources:
    PharmGKB

  • OLANZAPINE   ADRA2A

    Interaction Score: 0.03

    Interaction Types & Directionality:
    antagonist (inhibitory)

    Interaction Info:
    Trial Name olanzapine,Zyprexa, Zypadhera, Zyprexa Relprevv
    Novel drug target Established target
    Trial Name Olanzapine/fluoxetine combination,Symbyax (Zyprexa/Prozac)

    PMIDs:
    17848919


    Sources:
    TdgClinicalTrial

  • OLANZAPINE   GFER

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OLANZAPINE   CYP3A5

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23559402


    Sources:
    PharmGKB

  • OLANZAPINE   ABCB1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29443543 18086475 17038883


    Sources:
    PharmGKB

  • OLANZAPINE   PPARG

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    19622037


    Sources:
    PharmGKB

  • OLANZAPINE   GAA

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • OLANZAPINE   GLP1R

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24624910


    Sources:
    PharmGKB

  • OLANZAPINE   RGS4

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • OLANZAPINE   CYP2C9

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23559402


    Sources:
    PharmGKB

  • OLANZAPINE   CYP3A4

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23559402


    Sources:
    PharmGKB

  • TEND: OLANZAPINE

    • Version: 01-August-2011

    Alternate Names:
    OLANZAPINE Primary Drug Name

    Drug Info:
    Drug Class antipsychotic agents
    Year of Approval 1996

    Publications:

  • TdgClinicalTrial: OLANZAPINE

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antipsychotic agent
    Drug Class Small Molecule
    FDA Approval approved

    Publications:

  • PharmGKB: olanzapine

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Tiwari AK et al., 2010, Association study of polymorphisms in cholecystokinin gene and its receptors with antipsychotic induced weight gain in schizophrenia patients., Prog Neuropsychopharmacol Biol Psychiatry
    Ono S et al., 2015, GIPR Gene Polymorphism and Weight Gain in Patients With Schizophrenia Treated With Olanzapine., J Neuropsychiatry Clin Neurosci
    Ono S et al., 2012, Association between the GIPR gene and the insulin level after glucose loading in schizophrenia patients treated with olanzapine., Pharmacogenomics J

  • TTD: Olanzapine

    • Version: 2020.06.01

    Alternate Names:
    D0V4QS TTD Drug ID

    Drug Info:

    Publications:

  • DTC: OLANZAPINE

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL715 ChEMBL Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL715

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL715

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21